News from durect corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 16, 2014, 08:00 ET

DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product

 DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen...

Dec 01, 2014, 16:30 ET

DURECT to Present at the Oppenheimer Healthcare Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual...

Nov 11, 2014, 16:05 ET

DURECT Provides Update on POSIDUR™ Program

 DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23,...

Nov 03, 2014, 16:05 ET

DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014.  Total revenues were $4.3 million and net...

Oct 27, 2014, 08:05 ET

DURECT Provides Update on REMOXY® and POSIDUR™ Programs

 DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc....

Oct 24, 2014, 16:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time.

DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the...

Oct 10, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the American Society of Anesthesiologists Annual Meeting

DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...

Aug 25, 2014, 16:15 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT to Present at the Rodman & Renshaw Investment Conference

 DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Rodman & Renshaw...

Aug 07, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of Programs

 DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014.  Total revenues were $4.6 million and...

Jul 30, 2014, 16:15 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2014 financial results press release, you are invited to listen to the...

Jun 26, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Secures $20 Million Debt Financing

DURECT Corporation (Nasdaq: DRRX) today announced that it had entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance...

Jun 09, 2014, 08:00 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at The 25th Annual Wall Street...

May 16, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia Research Society (IARS) Annual Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...

May 07, 2014, 08:30 ET

DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at...

May 01, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces First Quarter 2014 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014.  Total revenues were $6.3 million and net...

Apr 23, 2014, 17:40 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the...

Apr 01, 2014, 16:15 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...

Feb 27, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million...

Feb 18, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the...

Feb 12, 2014, 16:43 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)

DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for...